Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

May 19, 2018

Primary Completion Date

July 31, 2019

Study Completion Date

October 1, 2019

Conditions
Adenomyosis
Interventions
DRUG

Mifepristone

Oral mifepristone 10mg (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating

DRUG

Placebo

Oral Placebo Oral Tablet 1# (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating

Trial Locations (1)

Unknown

Women's Hospital of Zhejiang Medical University, Hangzhou

All Listed Sponsors
collaborator

Anhui Province Cancer Hospital

UNKNOWN

collaborator

Huzhou Maternity and Child Care Hospital

UNKNOWN

collaborator

Jiaxing Maternity and Child Health Care Hospital

OTHER

collaborator

Jinhua Municipal Central Hospital

OTHER

collaborator

The Central Hospital of Lishui City

OTHER

collaborator

The Affiliated Hospital of Medical School of Ningbo University

UNKNOWN

collaborator

Ningbo Maternity and Child Care Hospital

UNKNOWN

collaborator

The People's Hospital of Quzhou

OTHER

collaborator

Shaoxing Women and Children's Hospital

UNKNOWN

collaborator

First Affiliated Hospital of Wenzhou Medical University

OTHER

collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

collaborator

Sir Run Run Shaw Hospital

OTHER

collaborator

Taizhou First People's Hospital

OTHER

collaborator

Zhoushan Maternity and Infant Hospital

UNKNOWN

collaborator

Shaoxing People's Hospital

OTHER

lead

xinmei zhang

OTHER

NCT03520439 - Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis | Biotech Hunter | Biotech Hunter